Advertisement


Eva M. Ciruelos, MD, PhD, on HER2-Positive Breast Cancer: Results From the PATRICIA Trial

2018 San Antonio Breast Cancer Symposium

Advertisement

Eva M. Ciruelos, MD, PhD, of the University Hospital 12 de Octubre and the SOLTI Group, discusses study findings on palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer (Abstract PD3-03).



Related Videos

Breast Cancer
Genomics/Genetics

Dejan Juric, MD, on Advanced Breast Cancer: Results From the SOLAR-1 Trial

Dejan Juric, MD, of Massachusetts General Hospital, discusses phase III study findings on liquid biopsy–based assessment of PIK3CA mutational status and the combination of the selective PI3K-alpha inhibitor alpelisib plus fulvestrant in the treatment of advanced breast cancer (Abstract GS3-08).

Breast Cancer
Issues in Oncology

Roberto A. Leon-Ferre, MD, on Decreasing Hot Flashes: Results From an ACCRU Trial

Roberto A. Leon-Ferre, MD, of the Mayo Clinic, discusses study findings on the effectiveness of oxybutynin in decreasing the frequency and severity of hot flashes (Abstract GS6-01).

Breast Cancer

Kathryn J. Ruddy, MD, MPH, on Breast Cancer and Quality of Life: Expert Perspective

Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic, summarizes a special spotlight session that included discussion of interventions to improve quality of life and the importance of lifestyle in the prevention of cancer and cancer recurrence.

Breast Cancer

Monica Morrow, MD, on View From the Trenches: What Will You do on Monday Morning?

Monica Morrow, MD, of Memorial Sloan Kettering Cancer Center reviews lessons learned from top abstracts, including how to tailor the extent of local therapy to minimize morbidity, the diminishing role of axillary lymph node dissection, long-term sequelae of breast surgical procedures, and the need to discuss outcomes with patients.

Breast Cancer
Genomics/Genetics

Judy E. Garber, MD, on Cancer Genetics: Updates for Breast Cancer Care

Judy E. Garber, MD, of the Dana-Farber Cancer Institute, summarizes a special session she moderated, which included discussion of polygenic risk scores, genetic testing in diverse populations, and what to do when presented with moderate-penetrance mutations.

Advertisement

Advertisement




Advertisement